Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report
DOI:
https://doi.org/10.2340/actadv.v104.40800Keywords:
Atopic dermatitis, hypereosinophilia, Dupilumab, TralokinumabAbstract
Abstract is missing (Short communication)
Downloads
References
Ferrucci S, Angileri L, Tavecchio S, Fumagalli S, Iurlo A, Cattaneo D, et al. Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease. J Dermatolog Treat 2022; 33: 2587-2592.
https://doi.org/10.1080/09546634.2022.2049588 DOI: https://doi.org/10.1080/09546634.2022.2049588
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184: 437-449.
https://doi.org/10.1111/bjd.19574 DOI: https://doi.org/10.1111/bjd.19574
Panettieri RA Jr, Sjöbring U, Péterffy A, Wessman P, Bowen K, Piper E, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med 2018; 6: 511-525.
https://doi.org/10.1016/S2213-2600(18)30184-X DOI: https://doi.org/10.1016/S2213-2600(18)30184-X
Caminati M, Olivieri B, Dama A, Micheletto C, Paggiaro P, Pinter P, et al. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med 2022; 16: 713-721.
https://doi.org/10.1080/17476348.2022.2090342 DOI: https://doi.org/10.1080/17476348.2022.2090342
Eger K, Pet L, Weersink EJM, Bel EH. Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract 2021; 9: 2913-2915.
https://doi.org/10.1016/j.jaip.2021.02.042 DOI: https://doi.org/10.1016/j.jaip.2021.02.042
Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract 2022; 10: 2695-2709.
https://doi.org/10.1016/j.jaip.2022.05.019 DOI: https://doi.org/10.1016/j.jaip.2022.05.019
Kuang FL, Khoury P, Weller PF, Wechsler ME, Klion AD. Biologics and hypereosinophilic syndromes: knowledge gaps and controversies. J Allergy Clin Immunol Pract. 2023; 11: 2666-2671.
https://doi.org/10.1016/j.jaip.2023.07.026 DOI: https://doi.org/10.1016/j.jaip.2023.07.026
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378: 2486-2496.
https://doi.org/10.1056/NEJMoa1804092 DOI: https://doi.org/10.1056/NEJMoa1804092
Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol 2017; 176: 553-572.
https://doi.org/10.1111/bjh.14488 DOI: https://doi.org/10.1111/bjh.14488
Leru PM. Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. Clin Transl Allergy 2019; 9: 36.
https://doi.org/10.1186/s13601-019-0277-4 DOI: https://doi.org/10.1186/s13601-019-0277-4
Menzella F, Montanari G, Patricelli G, Cavazza A, Galeone C, Ruggiero P, et al. A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Ther Clin Risk Manag 2019; 15: 869-875.
https://doi.org/10.2147/TCRM.S207402 DOI: https://doi.org/10.2147/TCRM.S207402
Bjerrum OW, Siersma V, Hasselbalch HC, Lind B, Andersen CL. Association of the blood eosinophil count with end-organ symptoms. Ann Med Surg (Lond) 2019; 45: 11-18.
https://doi.org/10.1016/j.amsu.2019.06.015 DOI: https://doi.org/10.1016/j.amsu.2019.06.015
Zhou X, Yang G, Zeng X, Wang L, Xiang J, Zhao J, et al. Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis. Front Immunol 2024; 14: 1277734.
https://doi.org/10.3389/fimmu.2023.1277734 DOI: https://doi.org/10.3389/fimmu.2023.1277734
Yamamoto H, Nagata M, Sakamoto Y. CC chemokines and transmigration of eosinophils in the presence of vascular cell adhesion molecule 1. Ann Allergy Asthma Immunol 2005; 94: 292-300.
https://doi.org/10.1016/S1081-1206(10)61311-7 DOI: https://doi.org/10.1016/S1081-1206(10)61311-7
Iftikhar IH, Schimmel M, Bender W, Swenson C, Amrol D. Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung 2018; 196: 517-530.
https://doi.org/10.1007/s00408-018-0151-5 DOI: https://doi.org/10.1007/s00408-018-0151-5
Published
How to Cite
License
Copyright (c) 2024 Ilaria Trave, Ilaria Salvi, Diego Bagnasco, Aurora Parodi, Emanuele Cozzani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
